{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:21:42Z","timestamp":1778800902967,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejpn.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T01:59:14Z","timestamp":1653357554000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments"],"prefix":"10.1016","volume":"39","author":[{"given":"Anupam","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail M.","family":"Farfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-2862","authenticated-orcid":false,"given":"Arnold R.","family":"Gammaitoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-5887","authenticated-orcid":false,"given":"Pierre C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8034-4529","authenticated-orcid":false,"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S.","family":"Galer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2022.05.006_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2022.05.006_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejpn.2022.05.006_bib4","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","author":"Bowen","year":"1997","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ejpn.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","article-title":"Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population","volume":"33","author":"Schoonjans","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejpn.2022.05.006_bib7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A\u00a0phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects","volume":"57","author":"Boyd","year":"2019","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejpn.2022.05.006_bib9","series-title":"Presented at American Epilepsy Society Annual Meeting","article-title":"ZX008 (fenfluramine oral solution) as adjunctive therapy for Dravet syndrome seizures: a pharmacometric approach to quantify potential drug-drug interactions to support phase 3 dose selection","author":"Rubino","year":"2017"},{"key":"10.1016\/j.ejpn.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.echo.2009.05.020","article-title":"Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation","volume":"22","author":"Douglas","year":"2009","journal-title":"J.\u00a0Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ejpn.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J.\u00a0Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ejpn.2022.05.006_bib12","series-title":"Presented at American Epilepsy Society Virtual Annual Meeting","article-title":"Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (Study 3)","author":"Sullivan","year":"2020"},{"key":"10.1016\/j.ejpn.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1741-7015-6-34","article-title":"Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals","volume":"6","author":"Dahl","year":"2008","journal-title":"BMC Med."},{"key":"10.1016\/j.ejpn.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2261-3-5","article-title":"Risk of valvular heart disease associated with use of fenfluramine","volume":"3","author":"Hopkins","year":"2003","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ejpn.2022.05.006_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A\u00a0population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation","volume":"339","author":"Jick","year":"1998","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.05.006_bib16","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.ijo.0801020","article-title":"Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy","volume":"23","author":"Li","year":"1999","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.ejpn.2022.05.006_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/14740330902931524","article-title":"Serotonergic drugs and valvular heart disease","volume":"8","author":"Rothman","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejpn.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejpn.2022.05.006_bib19","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:05Z","timestamp":1761071945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"alternative-id":["S1090379822000848"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.05.006","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}